Analysts See $-0.29 EPS for Soligenix, Inc. (SNGX); EVOLVA HOLDING AG NAMEN -AKT- SWITZERLA (ELVAF) Sellers Increased By 10.77% Their Shorts

April 17, 2018 - By Hazel Jackson

Evolva Holding SA (OTCMKTS:ELVAF) Logo

Analysts expect Soligenix, Inc. (NASDAQ:SNGX) to report $-0.29 EPS on May, 10.They anticipate $0.03 EPS change or 9.38% from last quarter’s $-0.32 EPS. The stock increased 2.30% or $0.04 during the last trading session, reaching $1.78. About 23,891 shares traded. Soligenix, Inc. (NASDAQ:SNGX) has declined 18.37% since April 17, 2017 and is downtrending. It has underperformed by 29.92% the S&P500.

EVOLVA HOLDING AG NAMEN -AKT- SWITZERLA (OTCMKTS:ELVAF) had an increase of 10.77% in short interest. ELVAF’s SI was 4.84 million shares in April as released by FINRA. Its up 10.77% from 4.37 million shares previously. With 15,600 avg volume, 311 days are for EVOLVA HOLDING AG NAMEN -AKT- SWITZERLA (OTCMKTS:ELVAF)’s short sellers to cover ELVAF’s short positions. The SI to EVOLVA HOLDING AG NAMEN -AKT- SWITZERLA’s float is 1.27%. It closed at $0.2966 lastly. It is down 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company has market cap of $15.56 million. It operates through two divisions, BioTherapeutics and Vaccines/BioDefense. It currently has negative earnings. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including pediatric Crohn's disease and acute radiation enteritis.

Evolva Holding SA develops and commercializes ingredients for use in food, nutrition, personal healthcare, agriculture, and other sectors in Switzerland, United States, Denmark, and internationally. The company has market cap of $208.12 million. The firm offers Resveratrol, a natural plant ingredient; Stevia, a natural sweetener; Saffron spices; Ruby, an ingredient for use in food, personal care, and other markets; Coral, an ingredient used in food and beverages; Ergot Alkaloids, a family of natural products for use in crop protection and pharmaceuticals; and Vanadium, an ingredient for use as agricultural bioactive. It currently has negative earnings. It also provides Nootkatone, a citrus ingredient; Agate, an ingredient used in personal care products; Opal, an ingredient for use in cosmetics and other markets; vanilla, a flavor and fragrance ingredient; Valencene, an orange flavor and fragrance ingredient used in food and drink, personal care, and household products; sandalwood oil; Agarwood for incense and perfume makers, and medicine practitioners; and Tourmaline, an ingredient for use in flavors and fragrances, as well as other markets.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>